|Bid||2.9000 x 1200|
|Ask||3.0000 x 1000|
|Day's range||2.9400 - 3.0400|
|52-week range||1.6800 - 3.8300|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||N/A|
|Earnings date||26 Oct 2023 - 30 Oct 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.26|
AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.
Investors need to pay close attention to AC Immune (ACIU) stock based on the movements in the options market lately.
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company will present a corporate overview and participate in one-on-one investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference, taking place virtually and in-perso